Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration

Ophthalmic Surgery Lasers and Imaging

Volumn 42, Issue 6, 2011, Pages 498-508

  Tran, Thi Ha Chau ^a,b   Querques, Giuseppe ^c   Forzy, Gerard ^b   Souied, Eric H ^c  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; DEMOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 83055166977     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20110804-04     Document Type: Article

References (16)

1. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116-126.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444. (Pubitemid 44511558)
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
4. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13.
5. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-252. (Pubitemid 46172497)
6. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857.
7. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.e41.
9. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409-413.
10. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology. 2009;116:1740-1747.
11. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol. 2009;147:831-837.
12. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol. 2010;94:292-296.
13. Cohen SY, Korobelnik JF, Tadayoni R, et al. Monitoring anti-VEGF drugs for treatment of exudative AMD [article in French]. J Fr Ophtalmol. 2007;30:330-334.
14. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053. (Pubitemid 40797460)
15. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther. 2008;30:2436-2451.
16. Prenner JL, Kaiser R, Chang TS. Perfused, but not leaking. Ophthalmology. 2009;116:1590.